Published in Medicine and Law Weekly, January 14th, 2005
Basilea and Ortho-McNeil Pharmaceutical, Inc, a Johnson & Johnson company, are in negotiations related to a potential license agreement on Basilea's phase 3, broad-spectrum cephalosporin antibiotic, ceftobiprole (BAL5788), that has activity against methicillin-resistant Staphylococcus aureus (MRSA).
Basilea has been in discussions with a number of potential partners related to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.